Wednesday, November 11, 2020 Daily Archives

Future Proof Your HCP Strategy

Future proof your HCP strategy. Four questions to help you decide if your HCP analysis data is ready for next phase approval. Host cell proteins (HCPs) are a primary source of impurities in biologics development. Scientists must detect and remove HCPs to ensure patient safety and meet regulatory guidelines. If previously undetected HCPs are found in later phases of clinical trials, scientists will need to redesign the drug substance purification strategy – adding financial and time costs that can create…

FPLC Column Selection Considerations

This webcast features: Dan Yukon, Head of North American Sales and Global Sales of SNAP Products, Astrea Bioseparations This presentation will outline various selection criteria when considering glass fast protein liquid chromatography (FPLC) columns for low-pressure chromatography. The topics will include: pressure and volume considerations column configuration (aspect ratio) materials of construction frit type, design porosity, and mounting connection types adjustability construction accuracy packing tube design storage. There are many types and brands of columns available on the market, and…

Novo Nordisk in $1.8bn deal for oral biologic tech

Novo Nordisk to acquire Emisphere Technologies and take ownership of Eligen drug delivery technology. The two companies have been partners since 2007, which culminated in the approval of Rybelsus (semaglutide). The glucagon-like peptide-1 (GLP-1) treatment for adults with type 2 diabetes became the first such treatment to be approved by the US Food and Drug Administration (FDA) for oral delivery last year. Rybelsus was created by Novo Nordisk under a license agreement with Emisphere, using the Eligen SNAC drug delivery…